Windhover.com | Medtech Insight | The RPM Report | Inteleos | EBI
Subscriber Username:   Password: Forgot Password?
Health Care Business Intelligence, Analysis, Insight - Windhover
Search


Receive Windhover's unique market insight fast with our free alert service 'Windhover's Update', including the latest abstracts and summaries from:

• IN VIVO
• Start-Up
• The RPM Report
• Medtech Insight


Sign up now

Since 1989, Windhover Information Inc. has been providing superior analysis and commentary on health care business strategy, industry dealmaking, marketplace trends, and the world of medical start-ups. The expertise that our editorial and research staff have developed--now consulted and relied upon by the industry's top executives, consultants, bankers and investors--finds voice in our publications, leading-edge conferences, and integrated, highly searchable databases of transactions and commentary. Windhover's editorial goal: to clearly present objective, accurate, fundamentally valuable decision-making information.

In March 2008, Windhover Information Inc. was acquired by Elsevier, the world’s leading publisher of science, technical and health information. In combining Windhover's analysis and commentary on business strategy, deal-making, and market trends, with the extensive and timely regulatory and reimbursement coverage of Elsevier's F-D-C Reports, we have built a comprehensive and interoperable source of information that biopharma and medical device professionals can rely upon to make critical business decisions.  Elsevier Business Intelligence is the name under which we will now be offering our full-line of products and services. For more information on this acquistion, view the press release here.

How we generate our content:

Windhover has amassed an unparalleled number of personal contacts at most companies in the pharmaceutical, biotech, medical device and diagnostic industries as well as in the investment banking, venture capital, consulting and other industry-support sectors. Our editorial and research staff leverages this extensive contact list in primary research, which we supplement with an extensive scanning, understanding and use of company and SEC documents. But whereas other information providers merely parrot back what they learn, Windhover's editors and writers use their extensive expertise in the industry to draw out the significance of the data, presenting not merely the facts but what we call the "so what" of trends, events, and strategies.

Related websites of interest:

Windhover Online (Subscribers) sis.windhover.com
Elsevier Business Intelligence www.elsevierbi.com
The RPM Report www.rpmreport.com
Medtech Insight www.medtechinsight.com
Company Profiles companies.windhover.com
The IN VIVO Blog invivoblog.blogspot.com
Elsevier www.elsevier.com


The IN VIVO Blog

Pharmaceutical Strategic Alliances
September 21-23, 2010 · New York, NY

PharmAsia Summit
October 25-26, 2010 · San Francisco, CA

IN3 Summit
October 27-29, 2010 · San Francisco, CA

Interested in presenting at a Windhover conference?
Submit your idea here


Novartis Follows Its Own Business Development Model into Molecular Diagnostics
Novartis is mirroring its approach to pharma R&D and leveraging the byproducts of its biomarker work there to build a commercial molecular diagnostics franchise. The head of the unit talks about its structure, strategy and programs. . . [MORE] (IN VIVO)

Bioactive Technologies For Bone Replacement
Expanded indications for bone morphogenetic proteins and new alternatives to those first-generation bone growth factors have the potential to grow the $2 billion market for bone replacement materials. . . [MORE] (Start-Up)

Laser Cataract Surgery Comes into Focus at ASCRS
The mood was primarily upbeat at April's annual meeting of the American Society of Cataract and Refractive Surgery. Most in attendance expected a modest rebound in procedure volumes for 2010. . . [MORE] (Medtech Insight)

FDA, Drug Development and Health Care Reform: A Panel Discussion
Current and former FDA officials and a former Big Pharma head of R&D discuss FDA and the relationship between a regulator and the industry it regulates when it comes to drug development. . . [MORE] (The RPM Report)

Read more from the latest: IN VIVO, Start-Up, The RPM Report, Medtech Insight, "The Pink Sheet", "The Pink Sheet" DAILY, "The Rose Sheet", "The Tan Sheet", PharmAsia News, Pharmaceutical Approvals Monthly, and "The Gray Sheet".




Pharma Deals
  FDA Has Full Plate This Fall for Vaccines: More Than H1N1
  GSK Slides Away From Innovation
  The Billion Dollar REMS: Xenazine?
Device Deals
  Stroke Devices: Facing Challenges Head On
  Vascular Closure Devices at the Crossroads
  What New Her2 Tests Say about Personalized Medicine

Interested in subscribing? Click here.
Publications - Databases - Conferences - Webinars - About Us - Contact Us - Help - The IN VIVO Blog - RSS Feeds - Company Profiles - Subscriber Login

Copyright © 2010, Windhover Information, Inc. An Elsevier company. All rights reserved.

Elsevier Business Intelligence